Cancer drug bills set to fall: NPPA lists steep MRP cuts in several medicines from Nov 9

New Delhi, Oct 29 (UNI) Cancer patients facing the burden of expensive medicines could get significant relief from November 9, with the National Pharmaceutical Pricing Authority (NPPA) publishing revised maximum retail prices (MRPs) for several non-scheduled anti-cancer drug formulations. The list shows sharp reductions in selected brands, potentially lowering medicine expenses for patients who require prolonged treatment. The scale of the reductions is evident in Abbott Healthcare's bevacizumab 400 mg injection, supplied in a 16 ml vial, whose listed MRP has fallen from Rs65,205.09 to Rs8,956.75. The price of the company's 100 mg injection in a 4 ml vial has…